Market Insights
Global listed-IVD-company financials and regulatory approvals — revenue, profit, R&D and sector landscape, by market. Updated semi-annually.
Revenue Leaders
Top 15 by H1 2026 revenue (RMB Bn)
Net Profit Leaders
Top 15 by H1 2026 net profit attributable to parent (RMB Bn)
Fastest Revenue Growth
Top 10 by YoY revenue growth (%)
Fastest Profit Growth
Top 10 by YoY net profit growth (%)
Highest R&D Intensity
Top 10 by R&D expense as % of revenue
Sector Landscape
Revenue scale, growth and profitability across nine sectors (H1 2026)
NMPA Approvals
IVD products approved by NMPA, Jan–Jun 2026 — by month, product type and registrant
Monthly approvals
Product type mix
- Reagent kits302
- Instruments37
- Controls30
- Calibrators13
- Reagents9
- Software4
Top 10 registrants by approvals
Industry Trends
From the IVD Industry Trend Report · H1 2026
Structural reset in the post-procurement era
Centralized procurement is shifting the industry from channel-driven to product- and cost-driven competition. Scaled leaders with installed analyzer fleets keep gaining share while smaller players diverge.
Profit concentrates at the top
Industry profit increasingly accrues to leaders, who contribute the vast majority of earnings. High-barrier segments such as chemiluminescence and biological raw materials retain high margins and steady growth.
Going global is now mandatory
With domestic growth slowing, overseas expansion has moved from optional to essential. Companies with international registrations, channels and local service are opening a second growth curve.
Barbell-shaped R&D spending
R&D intensity is polarizing: innovative molecular-diagnostics and raw-material firms invest heavily to build moats, while some traditional players cut R&D to protect earnings, widening the long-term gap.
Cash flow separates winners
As post-pandemic demand normalizes, operating cash flow and receivables become leading indicators. Companies with stable cash generation and collections better weather the cycle.
Biological raw materials & core components
The upstream biological-reagent and raw-material segment leads on growth and margin with broad domestic-substitution potential, regarded as the most resilient "golden segment" of the chain.
Source: H1 2026 listed-company reports and public NMPA registration data. Figures in RMB billion. For research only; not investment advice.